mTOR inhibitors stop cancer cells from dividing, but they rarely kill them. New work in Molecular Cell from Luke Gilbert & lab reveals a mechanism connecting mTOR signaling, cholesterol biology, and ferroptosis that could turn growth arrest into cancer cell death.
For decades, we’ve known that the ENPP1 K173Q variant raises type 2 diabetes risk, but not why.
New work from @songnanwang.bsky.social in @lingyinli.bsky.social's lab, in collaboration with @svenssonlab.bsky.social, shows that this variant may promote metabolic dysfunction in brown adipose tissue.
There is a somewhat new option to suggest a word, and it seems to have an impact. I’ve just suggested this and biallelic.
The latest edition of Re:Port is live! Check it out and make sure to subscribe to get the latest updates from openRxiv right to your inbox.
openrxiv.org/wp-content/u...
Thanks for the chance to contribute!
AI to understand the language of life.
Our review just published
nature.com/articles/s41...
Free access rdcu.be/e89lQ
Happy to have played a part in putting this together. It was definitely interesting to see what the model proposed for Evo-designed proteins from @brianhie.bsky.social‘s lab.
Thanks for the chance to contribute to this!
Gladstone researchers found that low-oxygen conditions cause red blood cells to act like “glucose sponges,” lowering blood sugar.
Arc Co-Founder and Executive Director Silvana Konermann is speaking at TED2026 in Vancouver (April 13-17). She'll be sharing her vision for Arc's Virtual Cell Initiative, recently announced as part of The Audacious Project's 2025 cohort, on one of the world's biggest stages.
I love a good high-altitude adaptation story:
"Therefore, we hypothesized that RBCs represent the primary glucose sink under hypoxic conditions (...) These findings uncover an unexpected yet fundamental role for RBCs in systemic glucose homeostasis, opening new avenues for diabetes therapies."
The LSEF JEDI Award provides 10 hours of expert editorial support to scientists from groups underrepresented in science. Deadline: March 10. Please share broadly: lifescienceeditors.org/apply/
With a year between preprint and publication, the publication milestone becomes a chance to reflect both on the additional validation added in revision and how the scientific community is using Evo 2 based on ~200 citations to the preprint & 10s of thousands of downloads of the model. Read more ⬇️
Custom lab bench Lego set with Arc Institute logo
And, if you’re lucky enough to already have custom lego sets with your institutes logo, you could probably swap them right in! @arcinstitute.org
This is very cool. I’m a bit worried about the use of “cookie elements” for what might be petri dishes. Maybe a lab safety problem?!?!?🙃
I just made an account and voted for this biology laboratory made of LEGO to "promote biological research and inspire more people into the world of biology". They need 10K votes. Reposting and/or voting below would be helpful. 🤗
beta.ideas.lego.com/product-idea...
🚨 🚨 NEW PUBLICATION 🚨 🚨 "Vitamin B2 and B3 nutrigenomics reveals a therapy for NAXD disease"
@arcinstitute.org
@ishahjain.bsky.social
@cp-cell.bsky.social
Most drug discovery starts with a disease & searches for a cure. New research out in Cell from Arc investigator Isha Jain’s lab flips this model, starting with a potential cure (vitamins) & systematically identifying which diseases it could treat.
A reminder that applications close Friday, Feb 27 for the Arc AIxBio Fellows Program.
Undergrads: propose and run your own AI + biology research project over 6–12 months, with mentorship from Arc scientists. Apply solo or as a team of 2–3.
arcinstitute.org/programs/aix...
People living at high altitude have better glucose tolerance & lower diabetes risk, but the mechanism behind why has remained a mystery. New research out in Cell Metabolism from Isha Jain's lab reveals an unexpected answer—red blood cells.
Most genetic interaction studies measure gene relationships in one condition, but environment can reshape which genes depend on each other.
Today in Molecular Cell, Luke Gilbert & team deliver the first systematic, multi-condition map of genetic rewiring in human cells.
Finding one mutation that improves a protein is hard. Finding five that work together is exponentially harder.
Today in @science.org, Hsu and Konermann labs present MULTI-evolve, a lab-in-the-loop framework that does it in just one machine learning-guided round.
Amazing collaboration with the Jain lab! The impact of systemic hypoxia on cancer!
In this Molecular Cell Voices piece, @genophoria.bsky.social comments on how he thinks about bridging bench and computational work: www.cell.com/molecular-ce...
An amazing day for science at the 2nd Annual Arc Symposium!
Thank you to everyone who joined us from our labs, technology centers, partner universities, and beyond. We are so grateful that you're part of our community.
Today I’m happy to release cyto, a tool I’ve developed at @arcinstitute.org to dramatically increase our computational throughput with 10x-flex single-cell processing by more than 16X!
A new paper from Jeffrey Wang, @genophoria.bsky.social, and team describes orphan non-coding RNAs, known as "oncRNAs," as cancer-emergent molecules with important roles in tumor identity and progression, and clinical monitoring across human cancers: www.cell.com/cell-reports...
In a new review published in @cp-neuron.bsky.social, @christophthaiss.bsky.social and team synthesize emerging research on intestinal interoception, highlighting how signals from the gut shape communication between the environment, the body, and the brain to maintain human health.
Predicting cell state in previously unseen conditions has typically required retraining for each new biological context. Today, Arc is releasing Stack, a foundation model that learns to simulate cell state under novel conditions directly at inference time, no fine-tuning required.
Today, we welcome Megan van Overbeek as our first Chief Scientific Officer.
At Arc, she'll drive the discovery of novel therapeutic strategies for complex diseases, bringing expertise that bridges fundamental research with therapeutic development.